Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015, ORI Capital is a venture capital firm based in Hong Kong that focuses on early-stage investments in the biotech sector. The firm was established by Simone Song, a former Goldman Sachs executive, and has since built a reputation for addressing high-mortality disease areas through innovative solutions in diagnostics, drug delivery, and therapeutics. ORI Capital has a global investment strategy, with a particular emphasis on the rapidly evolving biotech landscape in China.
As of 2024, ORI Capital has raised $260 million for its second fund, which is dedicated to early-stage biotech companies worldwide. The firm employs a proprietary AI research system known as ORIZON, which tracks over 31,000 healthcare companies and 62,000 key opinion leaders (KOLs). This technology enhances their ability to identify promising investment opportunities in the biotech field.
ORI Capital's team comprises specialists with diverse expertise, including data science and scientific research, enabling them to provide valuable insights and support to their portfolio companies. The firm is actively expanding its reach and influence in the biotech sector, particularly in China, where it aims to capitalize on the country's emergence as a leading player in global biotech.
ORI Capital invests primarily in early-stage biotech companies, with a strong focus on sectors such as diagnostics, drug delivery, and therapeutics. The firm targets investments in high-mortality disease areas, including oncology, cardiovascular diseases, and neurodegenerative disorders. This strategic focus allows ORI Capital to support the development of transformative therapies that can significantly improve patient outcomes.
The firm typically engages in Seed and Series A funding rounds, providing initial capital to innovative startups that align with its investment thesis. ORI Capital's investment strategy is characterized by a global perspective, with particular attention to the burgeoning biotech market in China. The firm employs a quantimental strategy that integrates AI-assisted big data with fundamental research to identify and evaluate potential investments.
In addition to financial support, ORI Capital seeks to add value to its portfolio companies through strategic guidance and access to its extensive network within the biotech industry. The firm’s proprietary AI system, ORIZON, plays a crucial role in tracking healthcare trends and identifying opportunities for investment, further enhancing its ability to support early-stage biotech ventures.
ORI Capital's portfolio includes several notable companies that are making significant strides in the biotech sector. Key investments include:
These companies exemplify ORI Capital's commitment to investing in innovative solutions that address critical health challenges, particularly in high-mortality disease areas.
Simone Song: Founder & Senior Partner. Simone has a background in investment banking at Goldman Sachs and has extensive experience in venture capital and biotech investments.
Dicky To: Partner. Dicky brings expertise in venture capital and has been involved in numerous successful biotech investments.
Gang Song, PhD: Operating Partner. Gang has a strong scientific background and focuses on operational aspects of portfolio companies.
Arnold Ching: Investment Associate. Arnold supports the investment team in evaluating potential opportunities and managing portfolio companies.
Alexander Li: Investment Analyst. Alexander conducts market research and analysis to inform investment decisions.
Ben Kong, PhD: Approach-specific Scientist. Ben specializes in scientific research and provides insights into the technical aspects of investments.
Becky Chan, PhD: Approach-specific Scientist. Becky focuses on research and development within the biotech sector.
Nico Zheng: Vice President. Nico plays a key role in managing relationships with portfolio companies and investors.
Paul Huang: Data Engineer. Paul develops and maintains the data infrastructure that supports ORI Capital's investment research.
Hannah Wang: Data Analyst. Hannah analyzes data trends to assist in investment evaluations.
Cathy Choi: Financial Controller. Cathy oversees financial operations and reporting for the firm.
Joyce Li: HR & Operation Manager. Joyce manages human resources and operational functions within the firm.
Sherry Liu: Executive Assistant. Sherry provides administrative support to the team.
To pitch ORI Capital, startups should send an email to info@ori-capital.com with a comprehensive pitch deck. The deck should include details about the business model, market opportunity, team background, and any preliminary data or results that support the technology.
Founders should expect a response within a few weeks, as the firm reviews pitches on a rolling basis. Warm introductions are preferred but not mandatory. Clear and concise communication is key to capturing the firm's interest.
In February 2024, ORI Capital successfully raised $260 million for its second life sciences fund, which focuses on early-stage biotech investments globally. This fund aims to capitalize on the growing opportunities in the biotech sector, particularly in high-mortality disease areas.
Additionally, ORI Capital is in the process of launching a third fund, targeting approximately $350 million. This upcoming fund will emphasize investments in China-based biotech companies and AI-driven drug discovery, reflecting the firm's commitment to leveraging advancements in technology within the healthcare sector.
Recent coverage of ORI Capital has appeared in various media outlets, including BioPharma Dive and Fierce Biotech, highlighting the firm's innovative approach to venture capital and its focus on high-impact biotech solutions.
What are ORI Capital's investment criteria?
ORI Capital focuses on early-stage biotech companies that are developing innovative solutions in diagnostics, drug delivery, and therapeutics. The firm specifically targets high-mortality disease areas, including oncology, cardiovascular, and neurodegenerative diseases.
How can startups apply or pitch to ORI Capital?
Startups interested in pitching to ORI Capital can reach out via email at info@ori-capital.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes ORI Capital different from other venture capital firms?
ORI Capital distinguishes itself through its proprietary AI research system, ORIZON, which tracks healthcare trends and identifies promising investment opportunities. This technology, combined with a focus on high-mortality disease areas, positions ORI Capital as a unique partner for biotech startups.
What is the geographic scope of ORI Capital's investments?
ORI Capital invests globally, with a particular emphasis on the biotech sector in China. The firm aims to capitalize on the growing biotech landscape in the region while also exploring opportunities in other markets.
What is the typical check size for investments made by ORI Capital?
While specific check sizes are not publicly disclosed, ORI Capital typically engages in Seed and Series A funding rounds, which generally involve investments ranging from hundreds of thousands to several million dollars.
What kind of post-investment involvement does ORI Capital have with its portfolio companies?
ORI Capital provides strategic guidance and support to its portfolio companies, leveraging its extensive network in the biotech industry. The firm aims to add value through mentorship and operational support, helping startups navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.